Mutations in DHDPSL Are Responsible For Primary Hyperoxaluria Type III  by Belostotsky, Ruth et al.
REPORT
Mutations in DHDPSL Are Responsible
For Primary Hyperoxaluria Type III
Ruth Belostotsky,1 Eric Seboun,2,8 Gregory H. Idelson,1,9 Dawn S. Milliner,3 Rachel Becker-Cohen,1,4
Choni Rinat,1,4 Carla G. Monico,3 Sofia Feinstein,1,4 Efrat Ben-Shalom,1,4 Daniella Magen,5
Irith Weissman,6 Celine Charon,7 and Yaacov Frishberg1,4,*
Primary hyperoxaluria (PH) is an autosomal-recessive disorder of endogenous oxalate synthesis characterized by accumulation of
calcium oxalate primarily in the kidney. Deficiencies of alanine-glyoxylate aminotransferase (AGT) or glyoxylate reductase (GRHPR)
are the two known causes of the disease (PH I and II, respectively). To determine the etiology of an as yet uncharacterized type of
PH, we selected a cohort of 15 non-PH I/PH II patients from eight unrelated families with calcium oxalate nephrolithiasis for high-
density SNP microarray analysis. We determined that mutations in an uncharacterized gene, DHDPSL, on chromosome 10 cause a third
type of PH (PH III). To overcome the difficulties in data analysis attributed to a state of compoundheterozygosity, we developed a strategy
of ‘‘heterozygosity mapping’’—a search for long heterozygous patterns unique to all patients in a given family and overlapping between
families, followed by reconstruction of haplotypes. This approach enabled us to determine an allelic fragment shared by all patients of
Ashkenazi Jewish descent and bearing a 3 bp deletion in DHDPSL. Overall, six mutations were detected: four missense mutations, one
in-frame deletion, and one splice-site mutation. Our assumption is that DHDPSL is the gene encoding 4-hydroxy-2-oxoglutarate
aldolase, catalyzing the final step in the metabolic pathway of hydroxyproline.Primary hyperoxaluria (PH) type I and type II are relatively
rare autosomal-recessive disorders of endogenous oxalate
synthesis. Overproduction of oxalate by the liver results
in marked hyperoxaluria. The calcium salt of oxalate is
highly insoluble; therefore, hyperoxaluria leads to renal
stone formation and nephrocalcinosis in childhood, fol-
lowed by progressive renal damage, renal failure, and
reduced life expectancy. Type I PH (MIM 259900) is caused
by absent, deficient, or mistargeted activity of the liver-
specific peroxisomal enzyme alanine-glyoxylate amino-
transferase (AGT; MIM 604285).1 PH II (MIM 260000) is
caused by deficiency of the enzyme glyoxylate reductase/
hydroxypyruvate reductase (GRHPR; MIM 604296).2
A third group of patients has been described with an
autosomal-recessive disorder having a phenotype similar
to that of PH I and PH II but not due to hepatic AGT or
GRHPR deficiency. These patients are referred to as non-
PH I/PH II patients.3 To date, non-PH I/PH II forms of
inherited PH account for approximately 5% of all cases.3
The specific etiology of the disease in these patients is
unknown. Possible pathogenetic mechanismsmay include
alterations in pathways of oxalate synthesis in the liver
and/or kidney or in tubular oxalate handling. The under-
lying cause remains elusive despite several attempts to
define additional genetic loci that could affect urinary
oxalate excretion resulting in stone formation. The possi-
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for this type of PH have been refuted.
High-density SNP microarray analysis is a promising
approach for identifying disease susceptibility genes. We
implemented this technique in trying to identify the
gene that in its mutated form causes non-type I/II PH.
The cohort consisted of 16 patients from nine unrelated
families: five of Ashkenazi Jewish descent and four of Euro-
pean American origin. The impetus to launch this project
was the presentation of two sisters from family 1 (II-9
and II-10) at 22 and 36 months of age with kidney stones
composed of calcium oxalate associated with persistent
elevation of urine oxalate and normal hepatic AGT and
GRHPR enzymatic activity (family 1, Figure 1A). A second,
unrelated Ashkenazi Jewish family (family 2) with two
children affected with non-type I/II PH, one of whom
(II-1) developed nephrolithiasis in infancy, was enrolled
(family 2, Figure 1A). After completion of this study, we
diagnosed non-type I/II PH in another child of Ashkenazi
Jewish descent who presented with nephrolithiasis in
infancy (family 3). Eight additional children with non-
type I/II PH from six unrelated families treated at the
Mayo Clinic Hyperoxaluria Center (Rochester, MN, USA)
were also included (Table 1). Of note, two of these families
were of Ashkenazi Jewish descent (families 11 and 12).
Family 1 is a nonconsanguineous Ashkenazi Jewish
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Figure 1. Alleles of Ashkenazi Jewish Families
(A) Pedigrees of families 1, 2, 11, and 12, which enabled us to identify DHDPSL and the pattern of adjacent SNPs.
(B) Distribution of the shared allele among Ashkenazi Jewish families. Black numbers indicate the length of the shared fragment, red
numbers indicate the length of the homozygous fragment, and the pink frame indicates the common fragment J. The lengths of the
fragments are presented in megabase pairs.(Figure 1A). Both parents were healthy, and the family
history was negative for nephrolithiasis in previous gener-
ations. Biochemical workup of the probands revealed
a persistent increase in urinary oxalate excretion (1.20 5
0.49 mmol/1.73 m2/d [range 0.54–2.24; normal values <
0.49]) with milder degree of glycolic aciduria (125.2 5
60.6 mmol/mmol creatinine [normal values¼ 6–90]). There
was normal urinary excretion of phosphate, citrate, glycer-
ate, and amino acids. The sisters II-9 and II-10 had normal
growth and development, without any signs of gastroin-
testinal illness that might point to secondary or enteric
hyperoxaluria.
The clinical characteristics of the entire cohort of 16
patients with non-type I/II PH from nine unrelated fami-
lies are displayed in Table 1. The proband in each family
presented with calcium oxalate renal stone disease in early
childhood (mean age 2.0 5 1.6 years). The clinical mani-
festations were hematuria, pain, and/or urinary tract infec-
tion. Biochemical analysis demonstrated persistent hyper-
oxaluria in all children, with mildly increased urinaryThe Americanglycolic aciduria in approximately half of them. In a
number of cases, there was hypercalciuria and/or hyperur-
icosuria, but those were unrelated to the incidence of
nephrolithiasis. The clinical characteristics of a subgroup
of children were previously described.4 The proband in
each family underwent liver biopsy, and themeasurements
of AGT and of GRHPR enzymatic activity were within
normal range. None had any signs or symptoms consistent
with enteric hyperoxaluria. The six children in Monico’s
report were confirmed to have normal enteric oxalate
absorption by [13C]oxalate testing.4 Taken together, they
were diagnosed as having a new recessive form of hyperox-
aluria: non-type I/II primary hyperoxaluria. Five individ-
uals never formed stones. Increased fluid intake was rec-
ommended for all. No specific therapy was provided in
patients from families 1–3. Children from families 11–16
received neutral phosphate therapy, and some were also
treated with citrate medication or thiazides. They all had
well-preserved renal function at most recent follow-up
clinic visit (Table 1). In all patients of Ashkenazi JewishJournal of Human Genetics 87, 392–399, September 10, 2010 393
Table 1. Clinical Characteristics of Patients with Non-Type I/II Primary Hyperoxaluria
Family Patient Sex
Age First
Stone (Years)
Age Last
Stone (Years)
Age Last
Follow-up
Serum Creatinine Last
Follow-up (mg/dl) Ethnicity
1 A F 1.8 1.8 11.8 0.8 AJ
B F 3 3 14.2 0.9 AJ
C F never – 14.2 0.8 AJ
D F never – 19.2 NA AJ
E F never – 21.2 NA AJ
2 A M 0.38 0.38 11.5 0.6 AJ
B F never – 14 NA AJ
3 A M 1.5 3.83 4.2 0.5 AJ
11 A M 2 5 14 0.8 AJ
12 A M 0.33 6 14 0.5 AJ
13 A M 0.75 23 23 1.1 EA
B M 2 2.25 20 0.9 EA
14 A M 5.4 13 15 0.7 EA
15 A F 0.83 19 24 0.8 EA
16 A M 4 12 12 0.9 EA
B M never – – NA EA
The following abbreviations are used: NA, not available; AJ, Ashkenazi Jewish; EA, European American.descent, there was no recurrence of stone formation
beyond 6 years of age despite the fact that the degree of
hyperoxaluria remained constant.
High-density SNP microarray analysis of 39 individuals
from eight unrelated nonconsanguineous families includ-
ing 15 affected individuals and all of their siblings and
parents was performed on an Affymetrix GeneChip
Human Mapping 250K Nsp Array (Centre National de
Genotypage, Evry, France). Family 3 was recruited later
and was not included in this analysis. All experiments
involving DNA from patients and their relatives were
performed after obtaining informed consent and were
approved by the Shaare Zedek Medical Center Ethics
Committee (number 1/09) and the National Committee
for Genetic Studies of the Israeli Ministry of Health
(number 019-2009) or the Mayo Clinic Rochester
Institutional Review Board. Genomic DNA was extracted
from lymphocytes via standard molecular biology tech-
niques. Linkage analyses under a recessive model with
penetrance ¼ 1 were performed with MERLIN software
for a combined set of all families and for individual fami-
lies. The analyses failed to detect loci with high LOD score.
The maximal LOD score of approximately 2.2 was contrib-
uted exclusively by family 1: a flat LOD score over several
Mbp on chromosomes 4 and 10. The relatively low LOD
score excluded the possibility that the affected children
from family 1 share disease alleles identical by descent
(inherited from a common ancestor). Indeed, no large
homozygous fragments shared only by the affected indi-
viduals were identified.394 The American Journal of Human Genetics 87, 392–399, SeptembIn order to overcome these obstacles, an analytic strategy
(heterozygosity mapping) was adopted that enabled us to
detect and refine the fragment of interest. Analysis of the
SNP pattern in the relevant regions on chromosomes 4
and 10 revealed identical heterozygous patterns in all
patients of family 1 that were distinct from their healthy
parents and siblings. These fragments were of 19.6 and
42.4 Mbp, respectively. This fits the compound heterozy-
gous origin of the disease in family 1. In family 2, we iden-
tified a heterozygous fragment of 35 Mbp on chromosome
10 unique to both affected children. This region partly
intersects with the corresponding fragment of family 1,
yielding a locus of 27.6 Mbp in length. The fact that
both families are of Ashkenazi Jewish origin led us to
consider that they might represent one clinical entity
with possible sharing of a founder mutation at least
in one allele on chromosome 10. A recent publication
showed that identity by descent between Ashkenazi Jewish
individuals exhibits high frequencies of shared segments
similar to those shared by fourth or fifth cousins in
a completely outbred population, although typically with
shorter segments.6 We implemented the approach of
homozygosity haplotype (HH), a haplotype defined only
by the homozygous SNPs obtained following omission of
the heterozygous SNPs.7,8 We searched for a fragment in
whichHHs of both families were identical. Such a fragment
would suggest that within this region, the two families
share at least one common disease allele. This approach
enabled us to narrow the genomic region of interest to
6.1 Mbp.er 10, 2010
Figure 2. DNA Sequencing of an Ampli-
con of Exon 7 of DHDPSL Demonstrating
the Deletion Mutation c.944_946delAGG
Found in All Ashkenazi Jewish Patients
and Two Additional Families
The red boxmarks the deletion. (Note: SNP
rs1124116 upstream of exon 7 should be
avoided in designing primers.)We subsequently reconstructed individual haplotypes in
the 6.1 Mbp locus of interest of the mother and father of
family 1 by using the microarray data derived from the
genetic analysis of the parents and the siblings. Compar-
ison of each haplotype of the affected individuals of family
1 with those of family 2 demonstrated that the SNP pattern
of the maternal allele (1M1) completely matched the
haplotype of both patients of family 2.
Families 11 and 12 (Figure 1A) were also of Ashkenazi
Jewish descent, so we used data from them to refine the
region of interest. All Ashkenazi Jewish patients were
found to share the pattern of the maternal allele (1M1);
however, the exact position of the homologous fragment
was different in each case. The intersection of all shared
regions resulted in a very small fragment (J) of 0.6 Mbp
in length (Figure 1B).
This locus contained altogether 19 characterized or
uncharacterized genes. A priority list for sequencing was
generated, taking into account the known or presumed
protein function, the expression in liver and/or kidney,
and, when available, the phenotype associatedwith a givenTable 2. Distribution of Mutations in DHDPSL among Children with Primary Hyperoxaluria Ty
Maternal Allele Paternal Allele
Mutation Lengtha Protein Mutation
Ashkenazi Jewish
Family 1 c.944_946delAGG 6.6 Mbp p.Glu315del c.860G>T
Family 2 c.944_946delAGG 6 Mbp p.Glu315del c.944_946delAG
Family 3 c.944_946delAGG ND p.Glu315del c.944_946delAG
Family 11 c.944_946delAGG 3.1 Mbp p.Glu315del c.944_946delAG
Family 12 c.944_946delAGG 4.4 Mbp p.Glu315del c.944_946delAG
European American
Family 13 c.289C>T – p.Arg97Cys c.944_946delAG
Family 14 c.209G>C – p.Arg70Pro c.701þ4G>T
Family 15 c.701þ4G>T <0.5 Mbp in-frame splice site c.944_946delAG
Family 16 (A) c.769T>G 8 Mbp p.Cys257Gly c.769T>G
Family 16 (B) – – – –
ND, not determined.
a Maximal length of fragment shared with the corresponding allele.
The American Journal of Human Genetmutated gene. DHDPSL (SwissProt
accession number Q86XE5) was
selected as the preferred candidate
gene based on its unique expression
pattern mostly in liver and kidneyand its presumed involvement in metabolic processes.
PCR primers were designed for amplification of the entire
coding region and the adjacent intron/exon boundaries
of DHDPSL by using NCBI Primer-BLAST (see Table S1
available online). Genomic DNA samples were subjected
to PCR amplification and direct sequencing. All patients
of families 2, 11, and 12 were found to be homozygous
for a deletion c.944_946delAGG leading to the loss of
one glutamic acid residue (Figure 2). As we had speculated,
all affected individuals in family 1 were compound hetero-
zygotes: they were heterozygous for this mutation in-
herited from their mother, whereas their paternal muta-
tion was c.860G>T (p.Gly287Val). Mutation screening of
DHDPSL in the Ashkenazi Jewish patient from family 3
confirmed that he was also homozygous for the deletion
allele. The c.944_946delAGG deletion was also detected
in two non-Jewish families (family 13 and family 15) in
a heterozygous fashion (Figure 2; Table 2.) The second
mutation in family 13 was c.289C>T, and the second
mutation in family 15 was c.701þ4G>T. Mutations were
also found in family 14 (compound heterozygouspe III
Lengtha Protein
– p.Gly287Val
G 1.8 Mbp p.Glu315del
G ND p.Glu315del
G 2.6 Mbp p.Glu315del
G 2.8 Mbp p.Glu315del
G <0.5 Mbp p.Glu315del
<0.5 Mbp in-frame splice site
G 1 Mbp p.Glu315del
8 Mbp p.Cys257Gly
–
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Figure 3. The Metabolic Pathways of
Oxalate Production in Humansc.209G>C and c.701þ4G>T) and in patient A from family
16 (homozygous c.769T>G). Out of 16 patients, we found
either homozygous or compound heterozygous mutations
in this gene in 15 cases. In every patient, it was confirmed
that mutations were found on separate alleles inherited
from their respective parents (Table 2). Only one patient
(16B) was found not to carry mutations in this gene. His
affected brother (patient 16A) was homozygous for
a missense mutation (c.769T>G). This phenomenon could
be attributable to erroneous diagnosis of non-type I/II
PH in patient 16B. In fact, review of the clinical data
demonstrated that this patient had had only transient
hyperoxaluria and had never formed a kidney stone,
which represents a phenotypic misclassification. In all,
six different mutations were detected: deletion of three
base pairs, four missense mutations, and a presumed
splice-site mutation. Whether the missense mutations are
expected to bear pathogenic consequences was assessed
by the PolyPhen predictor. Threemutations were described
as probably (c.860G>T and c.769T>G) or possibly
(c.209G>C) damaging and one (c.289C>T) as benign
(damaging in this context represents a nonneutral change
and may also refer to gain of function). The deletion
mutation skips one amino acid. The splice-site mutation
switches to another donor splice site 51 nucleotides down-
stream (predicted by the NetGene2 server) and results in
in-frame insertion of 17 amino acid residues. Unfortu-
nately, the splicing effect could not be confirmed, because
both patients carrying this mutation were lost to follow-up
and their RNA samples were unavailable to us. None of
the mutations introduces a premature stop codon. This
leaves the two modes of functional effect, namely loss of
function and activation, to still be potentially applicable.
We searched for the two mutations detected in families
1, 2, 3, 11, and 12 in 216 chromosomes of anonymous396 The American Journal of Human Genetics 87, 392–399, September 10, 2010DNA samples derived from healthy
unrelated Ashkenazi Jewish individ-
uals. None were found to carry either
of these mutations. Screening by
direct sequencing of exonic and
flanking intronic regions of DHDPSL
in 226 chromosomes of European
American control samples from
Mayo Clinic Rochester also confirmed
absence of any of the pathogenic vari-
ants in this population. These find-
ings exclude the possibility that the
genetic variants are merely polymor-
phisms. Analysis of haplotypes of
shared mutations confirmed in most
instances a founder effect as displayed
in Table 2. In three cases, the sharedhaplotype was less than 0.5 Mbp (10 SNPs) in length,
which leaves the option of a recurrent mutation valid.
The automatic annotation of DHDPSL describes it as a
mitochondrial dihydrodipicolinate synthase-like enzyme.
However, the homology between the protein encoded by
DHDPSL and the original enzyme DHDPS (SwissProt acces-
sion number P0A6L2) is rather poor (28% identities, 47%
positives), and, even more importantly, there is little
homology in the vicinity of the putative substrate-binding
region, residues 77 and 78 of DHDPSL. Neither lysine
biosynthesis nor sialic acid metabolism (for which DHDPS
is responsible) takes place in vertebrate mitochondria.
Taking these data together, we conclude that only general
annotation of the enzymatic function can be suggested:
a mitochondrial enzyme that belongs to the lyase family
and catalyzes a lyase reaction with pyruvate as one of
the products. We assumed that DHDPSL encodes a meta-
bolic rather than a regulatory or a transport protein and
that it is involved in glyoxylate synthesis. Oxalate is
a product of oxidation of glyoxylate by cytosolic lactate
dehydrogenase. Thus, the increased production and excre-
tion of oxalate would be a direct result of glyoxylate
overproduction.
Glyoxylate is produced in organisms via two pathways:
the oxidation of glycolate contributed by vegetable matter,
and catabolism of hydroxyproline supplied by turnover
of collagen and protein from animal products (Figure 3).
We assume that the enzyme encoded by DHDPSL is
involved in the hydroxyproline pathway, which takes
place solely in mitochondria. This pathway includes
four steps (Figure 4); the last one is catalyzed by a pyruvate
lyase enzyme, 4-hydroxy-2-oxoglutarate aldolase. We
speculated that the putative function of the protein
encoded by DHDPSL best matches the pyruvate lyase
reaction catalyzed by 4-hydroxy-2-oxoglutarate aldolase
Figure 4. The Metabolic Pathway of Hy-
droxyproline Degradation in Humans(4-hydroxy-2-oxoglutarate glyoxylate-lyase) (IUBMB en-
zyme nomenclature EC 4.1.3.16). This assumption was
based on similarities drawn between the DHDPSL product
and 4-hydroxy-2-oxoglutarate aldolase with regard to the
following parameters:
d Both enzymes are involved in glyoxylate metabolism.
d Both catalyze the pyruvate lyase reaction and contain
lysine in the active site necessary for the formation of
a Schiff base intermediate.
d Both are localized in the mitochondria.
d Both are strongly expressed in kidney and liver.
d Their corresponding molecular masses are 35 kDa and
36 kDa, respectively.
The mammalian gene encoding 4-hydroxy-2-oxogluta-
rate aldolase was unknown until now. However, the
protein has been extensively investigated, purified, and
characterized (see KEGG and references 9–12). Our assump-
tion that DHDPSL is the gene encoding 4-hydroxy-2-oxo-
glutarate aldolase, or KHGA, was supported by the compar-
ison of the amino acid composition of the protein encoded
by bovineDHDPSL, short of themitochondrial signal, with
the protein purified from the bovine kidney.12 Indeed,
there is almost complete identity between the putative
DHDPSL product and 4-hydroxy-2-oxoglutarate aldolase
as shown in Figure 5. These findings are in contrast to
the marked differences detected in the amino acid content
between the bovine KHGA protein and the same protein
from various eukaryotic species. Similar differences have
been demonstrated between the bovine KHGA and a
number of other lyases.
Prokaryotic organisms are divided into two superking-
doms: eubacteria and archaebacteria. The enzyme from eu-
bacteria E. coli that catalyzes this reaction, kgdA, shares no
similarity with DHDPSL and belongs to the ED aldolase
family. In archaebacteria, the kgdA enzymes are not similar
to the eubacterial enzymes and belong to the DHDPS/
N-acetylneuraminate pyruvate lyase family.13,14 The arch-
aebacteria are closer to eukaryotic mitochondria, and in
fact, the archaebacteria Halobacterium salinarum kgdA
enzyme does show homology with DHDPSL (33% identi-The American Journal of Human Genetties, 47% positives; NCBI Blast), in
particular in the region encompassing
the substrate-binding site.
Taking these data together, we spec-
ulate that the putative function of
the protein encoded by DHDPSL best
matches 4-hydroxy-2-oxoglutarate al-
dolase and suggest that in patients
with non-type I/II PH, this enzyme
bears activating mutations leading tooxalate overproduction. The relatively large number (six)
of different activating mutations could be explained, at
least in part, by the homotetramer structure of the enzyme
and the interactions between its subunits. Alternatively, in
compound heterozygous conditions, one mutation may
inactivate a portion of the product, for instance by altering
tetramer formation. This would result in an enzyme that is
completely encoded by the second allele bearing the acti-
vating mutation.15
Human His-DHDPSL was expressed in E. coli and affinity
purified (Figure S1). We failed, however, to determine the
presumed 4-hydroxy-2-oxoglutarate aldolase activity of
the recombinant protein. We speculate that the inability
to demonstrate the predicted activity may be the result of
misfolding of the recombinant protein in the bacterial
system, presumably as a result of the high hydrophobicity
of themolecule (grand average of hydropathicity index>0)
and the tetrameric composition. Studies aimed at assessing
the function of the DHDPSL wild-type and mutated gene
products expressed in different systems are underway.
We propose to name the form of PH caused bymutations
inDHDPSL primary hyperoxaluria type III (PH III). The role
of dietary hydroxyproline as a contributor to hyperoxalu-
ria in patients with type III PH warrants investigation.
Inhibitors of 4-hydroxy-2-oxoglutarate aldolase encoded
by this gene should be the optimal treatment for children
with this form of PH.Supplemental Data
Supplemental Data include one table and one figure and can be
found with this article online at http://www.cell.com/AJHG.
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